Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C2IA
|
|||
| Former ID |
DIB014301
|
|||
| Drug Name |
DPC-168
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Discontinued in Phase 1 | [1] | |
| Company |
Bristol-Myers Squibb Pharma Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H36FN3O2
|
|||
| Canonical SMILES |
CC(=O)C1=CC(=CC=C1)NC(=O)NC2CCCCC2CN3CCCC(C3)CC4=CC=C(C=C4)F
|
|||
| InChI |
1S/C28H36FN3O2/c1-20(33)23-8-4-9-26(17-23)30-28(34)31-27-10-3-2-7-24(27)19-32-15-5-6-22(18-32)16-21-11-13-25(29)14-12-21/h4,8-9,11-14,17,22,24,27H,2-3,5-7,10,15-16,18-19H2,1H3,(H2,30,31,34)/t22-,24?,27+/m0/s1
|
|||
| InChIKey |
ASRDPULQBHFPGU-RJCBHOSBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 3 (CCR3) | Target Info | Antagonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Viral carcinogenesis | ||||
| NetPath Pathway | IL3 Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| IL1 and megakaryotyces in obesity | ||||
| IL-3 Signaling Pathway | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015460) | |||
| REF 2 | CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.